Pictet Asset Management Holding SA Sells 9,200 Shares of Edwards Lifesciences Corporation $EW

Pictet Asset Management Holding SA decreased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 2.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 343,016 shares of the medical research company’s stock after selling 9,200 shares during the quarter. Pictet Asset Management Holding SA owned about 0.06% of Edwards Lifesciences worth $27,469,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of EW. MV Capital Management Inc. acquired a new position in Edwards Lifesciences in the fourth quarter valued at approximately $26,000. Hanson & Doremus Investment Management acquired a new stake in Edwards Lifesciences during the 1st quarter worth $25,000. Kemnay Advisory Services Inc. bought a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $27,000. JPL Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the 3rd quarter valued at $25,000. Finally, Hilton Head Capital Partners LLC bought a new position in shares of Edwards Lifesciences in the 4th quarter worth $28,000. 79.46% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on EW shares. Wolfe Research raised Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price objective for the company in a research note on Wednesday, April 1st. BTIG Research raised their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Tuesday. TD Cowen restated a “buy” rating and set a $104.00 target price (up from $97.00) on shares of Edwards Lifesciences in a research report on Tuesday, June 2nd. Robert W. Baird upped their price target on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research note on Friday, April 24th. Finally, Evercore reiterated an “outperform” rating and issued a $93.00 price target on shares of Edwards Lifesciences in a research report on Friday, April 24th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $96.39.

Edwards Lifesciences Stock Up 1.7%

NYSE:EW opened at $91.95 on Thursday. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $92.88. The stock has a 50-day moving average price of $85.06 and a two-hundred day moving average price of $83.41. The stock has a market cap of $52.95 billion, a price-to-earnings ratio of 48.91, a PEG ratio of 2.27 and a beta of 0.85. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The company had revenue of $1.65 billion for the quarter, compared to analyst estimates of $1.60 billion. During the same quarter last year, the firm posted $0.64 earnings per share. Edwards Lifesciences’s revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction that occurred on Thursday, April 9th. The shares were sold at an average price of $80.04, for a total value of $1,040,520.00. Following the completion of the transaction, the chief financial officer owned 39,699 shares in the company, valued at $3,177,507.96. This represents a 24.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the sale, the vice president directly owned 98,611 shares of the company’s stock, valued at $8,521,962.62. This represents a 19.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 58,977 shares of company stock worth $4,921,803. Corporate insiders own 0.31% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.